Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...

Pharmacogenomics: Identification of New Drug Targets

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Inhibitors of Bacterial DNA Synthesis

Inhibitors of Bacterial DNA Synthesis

Bacterial pathogens depend on precise and efficient DNA replication to sustain infection. Two type II topoisomerases—DNA gyrase and topoisomerase IV—are critical to this process, as they resolve DNA supercoiling and unlink chromosomes during replication. Fluoroquinolones, synthetic derivatives of quinolones, exploit this mechanism by stabilizing the transient DNA–enzyme cleavage complex, preventing strand religation, and causing lethal double-strand breaks. These antibiotics are selectively...

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Design of the Japan Kidney Association-Pemafibrate Intervention for Chronic Kidney Disease patients Study (JKAPI-CKD Study).

Clinical kidney journal·2026

Same author

Association between serum lactate dehydrogenase level and renal outcome in patients with advanced chronic kidney disease without diabetes mellitus.

Clinical and experimental nephrology·2026

Same author

Predicting Lifetime Risk of Kidney Failure Using Age and a Single eGFR Measurement.

Journal of clinical medicine·2026

Same author

A meta-analysis of albuminuria as a surrogate endpoint for kidney failure.

Nature medicine·2025

Same author

Clinical Implications of Slope of GFR in Clinical Trials of CKD Progression.

Clinical journal of the American Society of Nephrology : CJASN·2025

Same author

Dapagliflozin for the Treatment of Collagenofibrotic Glomerulopathy.

Internal medicine (Tokyo, Japan)·2025

Search research articles

Related Experiment Video

Updated: May 13, 2026

Protocol for the Solid-phase Synthesis of Oligomers of RNA Containing a 2'-O-thiophenylmethyl Modification and Characterization via Circular Dichroism

Protocol for the Solid-phase Synthesis of Oligomers of RNA Containing a 2'-O-thiophenylmethyl Modification and Characterization via Circular Dichroism

Published on: July 28, 2017

Oligonucleotidic therapeutics.

Yoshitaka Isaka¹, Enyu Imai, Shiro Takahara

¹Osaka University Graduate School of Medicine, Departments of Advanced Technology for Transplantation, Suite 565-0871, Japan +81 6 6879 3746; +81 6 6879 3749 ; isaka@att.med.osaka-u.ac.jp.

Expert Opinion on Drug Discovery

|March 20, 2013

Summary

This summary is machine-generated.

Oligonucleotide-based biopharmaceuticals show promise in suppressing disease progression. This review focuses on antisense oligonucleotides and small interfering RNAs for future therapeutic applications.

More Related Videos

Intrathecal Delivery of Antisense Oligonucleotides in the Rat Central Nervous System

Intrathecal Delivery of Antisense Oligonucleotides in the Rat Central Nervous System

Published on: October 29, 2019

Related Experiment Videos

Last Updated: May 13, 2026

Protocol for the Solid-phase Synthesis of Oligomers of RNA Containing a 2'-O-thiophenylmethyl Modification and Characterization via Circular Dichroism

Protocol for the Solid-phase Synthesis of Oligomers of RNA Containing a 2'-O-thiophenylmethyl Modification and Characterization via Circular Dichroism

Published on: July 28, 2017

Intrathecal Delivery of Antisense Oligonucleotides in the Rat Central Nervous System

Intrathecal Delivery of Antisense Oligonucleotides in the Rat Central Nervous System

Published on: October 29, 2019

Area of Science:

Biopharmaceuticals
Molecular Biology
Genetics

Background:

Oligonucleotide-based biopharmaceuticals are a growing class of therapeutics.
Various types exist, including plasmids, antisense oligonucleotides, ribozymes, DNAzymes, decoys, aptamers, and small interfering RNAs.
These molecules are designed to interfere with disease processes at the genetic or molecular level.

Purpose of the Study:

To review the mechanisms of action for oligonucleotide-based therapeutics.
To discuss the current and potential clinical applications of these therapies.
To highlight antisense oligonucleotides and small interfering RNAs as particularly promising future applications.

Main Methods:

Literature review and synthesis of existing research on oligonucleotide therapeutics.
Analysis of mechanisms of action for different oligonucleotide classes.
Evaluation of clinical trial data and future prospects for key oligonucleotide types.

Main Results:

Oligonucleotide-based drugs offer diverse mechanisms to suppress disease progression.
Antisense oligonucleotides and small interfering RNAs demonstrate significant therapeutic potential.
The field is rapidly advancing, with ongoing research into novel applications.

Conclusions:

Oligonucleotide therapeutics represent a powerful approach to disease management.
Antisense oligonucleotides and small interfering RNAs are leading candidates for future drug development.
Further research is warranted to fully realize the clinical potential of these innovative therapies.